Advaxis was a Delaware corporation when it was acquired by a shell corporation (in the official SEC sense)[REF] in November 2004 [REF].
In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer [REF].,[REF] .